PE20100447A1 - Solucion acuosa inyectable que contiene 4-[[(7r)-8-isopropil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-tetrahidropteridin-2-il]amino]-3-metoxi-n-[(1-ciclopropil-4-piperazinil)fenil]benzamida - Google Patents
Solucion acuosa inyectable que contiene 4-[[(7r)-8-isopropil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-tetrahidropteridin-2-il]amino]-3-metoxi-n-[(1-ciclopropil-4-piperazinil)fenil]benzamidaInfo
- Publication number
- PE20100447A1 PE20100447A1 PE2009001171A PE2009001171A PE20100447A1 PE 20100447 A1 PE20100447 A1 PE 20100447A1 PE 2009001171 A PE2009001171 A PE 2009001171A PE 2009001171 A PE2009001171 A PE 2009001171A PE 20100447 A1 PE20100447 A1 PE 20100447A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclopropil
- piperazinil
- isopropil
- tetrahydropteridin
- metoxy
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 229940102223 injectable solution Drugs 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN UNA FORMA DE SOLUCION ACUOSA INFUNDIBLE O INYECTABLE, PARA ADMINISTRACION PARENTERAL, QUE COMPRENDE: A) COMPUESTO DERIVADO DE DIHIDROPTERIDINONAS FORMULA (I), DONDE R1 ES H; R2 ES CH3-CH2-X2; R3 ES CH3-CH2(X3)-CH3; R4 ES CH3-O-X4: Ln-R5m ES (a); X2, X3, X4 Y X5 SON CADA UNO PUNTO DE UNION CON EL ENLACE; B) ACIDO O MEZCLA DE ACIDOS FISIOLOGICAMENTE ACEPTABLES, TALES COMO ACIDO ACETICO, ACIDO CITRICO, ACIDO TARTARICO, ENTRE OTROS; Y C) EXCIPIENTES TALES COMO EDTA, DEXTROSA, NaCl Y MANITOL. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO ONCOLOGICO DE CANCER DE CRECIMIENTO RAPIDO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04019363 | 2004-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100447A1 true PE20100447A1 (es) | 2010-06-25 |
Family
ID=34926183
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009001171A PE20100447A1 (es) | 2004-08-14 | 2005-08-12 | Solucion acuosa inyectable que contiene 4-[[(7r)-8-isopropil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-tetrahidropteridin-2-il]amino]-3-metoxi-n-[(1-ciclopropil-4-piperazinil)fenil]benzamida |
| PE2009000399A PE20091583A1 (es) | 2004-08-14 | 2005-08-12 | Solucion para infusion de dihidropteridinonas estabilizada para el almacenamiento |
| PE2005000937A PE20060645A1 (es) | 2004-08-14 | 2005-08-12 | Solucion para infusion de dihidropteridinonas estabilizada para el almacenamiento |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000399A PE20091583A1 (es) | 2004-08-14 | 2005-08-12 | Solucion para infusion de dihidropteridinonas estabilizada para el almacenamiento |
| PE2005000937A PE20060645A1 (es) | 2004-08-14 | 2005-08-12 | Solucion para infusion de dihidropteridinonas estabilizada para el almacenamiento |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US20060035903A1 (es) |
| EP (1) | EP1778238B1 (es) |
| JP (1) | JP5048491B2 (es) |
| KR (1) | KR101235092B1 (es) |
| CN (2) | CN101039676A (es) |
| AR (1) | AR050918A1 (es) |
| AT (1) | ATE528007T1 (es) |
| AU (1) | AU2005274339B2 (es) |
| BR (1) | BRPI0513997A (es) |
| CA (1) | CA2575821C (es) |
| CY (1) | CY1112211T1 (es) |
| DK (1) | DK1778238T3 (es) |
| EA (1) | EA014237B1 (es) |
| EC (1) | ECSP077250A (es) |
| ES (1) | ES2375980T3 (es) |
| HR (1) | HRP20110966T1 (es) |
| IL (1) | IL181306A (es) |
| ME (1) | ME01264B (es) |
| MX (1) | MX2007001855A (es) |
| MY (1) | MY147799A (es) |
| NO (1) | NO20070984L (es) |
| NZ (1) | NZ553815A (es) |
| PE (3) | PE20100447A1 (es) |
| PL (1) | PL1778238T3 (es) |
| PT (1) | PT1778238E (es) |
| RS (1) | RS52043B (es) |
| SI (1) | SI1778238T1 (es) |
| TW (1) | TWI371278B (es) |
| UA (1) | UA92470C2 (es) |
| UY (1) | UY29060A1 (es) |
| WO (1) | WO2006018221A1 (es) |
| ZA (1) | ZA200700425B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| KR101504669B1 (ko) * | 2006-10-19 | 2015-03-20 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도 |
| GB0621203D0 (en) * | 2006-10-25 | 2006-12-06 | Chroma Therapeutics Ltd | PLK inhibitors |
| CA2695406A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| WO2009067547A1 (en) * | 2007-11-19 | 2009-05-28 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| CN102190669A (zh) * | 2010-03-19 | 2011-09-21 | 江苏恒瑞医药股份有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| AU2011252808B2 (en) | 2010-05-14 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
| EP2569434B1 (en) | 2010-05-14 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia and related disorders |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| ES2533042T3 (es) | 2011-02-25 | 2015-04-07 | Takeda Pharmaceutical Company Limited | Oxazinopteridinas y oxazinopteridinonas N-sustituidas |
| US20130131069A1 (en) | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| WO2013049033A1 (en) * | 2011-09-26 | 2013-04-04 | Cary Douglas D | Bladder catheter irrigation method and composition |
| UY34893A (es) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | Derivados de azaindol |
| US20140154304A1 (en) | 2012-11-30 | 2014-06-05 | Boehringer Ingelheim International Gmbh | Combination therapy with volasertib |
| WO2014159392A1 (en) | 2013-03-14 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| US9975896B2 (en) | 2013-07-25 | 2018-05-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| EP3066101B1 (en) | 2013-11-08 | 2020-07-29 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| UY35945A (es) | 2014-01-09 | 2015-08-31 | Takeda Pharmaceutical | Derivados de azaindol |
| MX2016009975A (es) * | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de dihidropteridinona y sus usos. |
| HK1225383A1 (zh) | 2014-01-31 | 2017-09-08 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| CN106029653A (zh) | 2014-01-31 | 2016-10-12 | 达纳-法伯癌症研究所股份有限公司 | 二氨基嘧啶苯砜衍生物及其用途 |
| CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
| MX2017001757A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de dihidropteridinona y sus usos. |
| BR112017002369A2 (pt) | 2014-08-08 | 2017-12-05 | Dana Farber Cancer Inst Inc | derivados de diazepana e usos dos mesmos |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016171446A1 (ko) * | 2015-04-20 | 2016-10-27 | 동아에스티 주식회사 | 펩타이드 붕소산 화합물을 함유하는 안정화 약학 제제 |
| RU2750164C2 (ru) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
| PE20181086A1 (es) | 2015-09-11 | 2018-07-05 | Dana Farber Cancer Inst Inc | Acetamida tienotrizolodiazepinas y usos de las mismas |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| WO2019145410A1 (en) | 2018-01-25 | 2019-08-01 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia |
| JP7400180B2 (ja) * | 2018-02-02 | 2023-12-19 | ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） | 非経口製剤及びその使用 |
| CN109400608B (zh) * | 2018-12-15 | 2021-08-31 | 西南大学 | 二氮杂螺[4，5]癸烷酒石酸类衍生物制备和应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8303657A (nl) | 1983-10-24 | 1985-05-17 | Pharmachemie Bv | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. |
| DE3537761A1 (de) * | 1985-10-24 | 1987-04-30 | Bayer Ag | Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure |
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| JPH0276860A (ja) | 1987-10-05 | 1990-03-16 | Toyo Jozo Co Ltd | ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体 |
| FR2645152B1 (fr) * | 1989-03-30 | 1991-05-31 | Lipha | 3h-pteridinones-4, procedes de preparation et medicaments les contenant |
| CA2029651C (en) | 1989-11-17 | 2000-06-06 | David D. Davey | Tricyclic pteridinones and a process for their preparation |
| US5198547A (en) | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| TW274550B (es) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| GB9418499D0 (en) | 1994-09-14 | 1994-11-02 | Ciba Geigy Ag | Process for producing n-methylated organic pigments |
| CO4410191A1 (es) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| CZ289721B6 (cs) | 1995-05-19 | 2002-03-13 | Syngenta Participations Ag | Způsob katalytické hydrogenace aromatických nitrosloučenin |
| US5698556A (en) * | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
| CN1146567C (zh) | 1996-09-23 | 2004-04-21 | 伊莱利利公司 | 奥氮平二水合物d |
| SK1822001A3 (en) | 1998-08-11 | 2002-08-06 | Pfizer Prod Inc | Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors |
| WO2001019825A1 (en) | 1999-09-15 | 2001-03-22 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| HUP0300136A2 (en) | 2000-03-06 | 2003-05-28 | Warner Lambert Co | 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
| DE10018783A1 (de) * | 2000-04-15 | 2001-10-25 | Fresenius Kabi De Gmbh | Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt |
| US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| DE10058119A1 (de) * | 2000-11-22 | 2002-05-23 | Bayer Ag | Pepinotan-Kit |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| HRP20040213A2 (en) | 2001-09-04 | 2005-02-28 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| AU2002217111B2 (en) | 2001-12-14 | 2007-05-31 | Merck Serono Sa | Methods of inducing ovulation using a non-polypeptide cAMP level modulator |
| HRP20041142A2 (en) | 2002-05-03 | 2005-10-31 | Schering Aktiengesellschaft | Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| FR2843114B1 (fr) | 2002-08-01 | 2004-09-10 | Poudres & Explosifs Ste Nale | Procede de monomethylation d'heterocycles azotes |
| CN1688576A (zh) | 2002-08-08 | 2005-10-26 | 史密丝克莱恩比彻姆公司 | 噻吩化合物 |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| HRP20050735B1 (hr) | 2003-02-26 | 2013-08-31 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Dihidropteridinoni, metoda za njihovu proizvodnju i upotrebu u obliku lijekova |
| MXPA05008526A (es) | 2003-03-26 | 2005-10-20 | Wyeth Corp | Metodos y composicion inmunogenica. |
| WO2004093848A2 (en) | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| JP2007517828A (ja) | 2004-01-17 | 2007-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 気道の疾患を治療するための置換プテリジンの使用 |
| DE102004002557A1 (de) | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| DE102004034623A1 (de) * | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| EP1632493A1 (de) | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2006021547A1 (de) | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinone als plk (polo like kinase) inhibitoren |
| EP1784406A1 (de) | 2004-08-27 | 2007-05-16 | Boehringer Ingelheim International GmbH | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| JP2009503014A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療におけるジヒドロプテリジノン |
| PL1948180T3 (pl) | 2005-11-11 | 2013-09-30 | Boehringer Ingelheim Int | Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2 |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| WO2007102767A1 (en) | 2006-03-07 | 2007-09-13 | Astrazeneca Ab | Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them |
| KR101541791B1 (ko) | 2006-05-04 | 2015-08-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| CA2695406A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| JP4642085B2 (ja) | 2008-01-17 | 2011-03-02 | 日本下水道事業団 | 予測健全度を利用した施設管理および更新計画システム |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| US20120329803A1 (en) | 2010-02-17 | 2012-12-27 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for production and use thereof |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US20130131069A1 (en) | 2011-05-13 | 2013-05-23 | Boehringer Ingelheim International Gmbh | Method for treatment of solid malignancies including advanced or metastatic solid malignancies |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
-
2005
- 2005-08-05 US US11/197,927 patent/US20060035903A1/en not_active Abandoned
- 2005-08-11 EP EP05778137A patent/EP1778238B1/de not_active Expired - Lifetime
- 2005-08-11 ES ES05778137T patent/ES2375980T3/es not_active Expired - Lifetime
- 2005-08-11 BR BRPI0513997-0A patent/BRPI0513997A/pt active Search and Examination
- 2005-08-11 WO PCT/EP2005/008735 patent/WO2006018221A1/de not_active Ceased
- 2005-08-11 DK DK05778137.9T patent/DK1778238T3/da active
- 2005-08-11 AU AU2005274339A patent/AU2005274339B2/en not_active Ceased
- 2005-08-11 PT PT05778137T patent/PT1778238E/pt unknown
- 2005-08-11 UA UAA200702575A patent/UA92470C2/ru unknown
- 2005-08-11 AT AT05778137T patent/ATE528007T1/de active
- 2005-08-11 RS RS20110504A patent/RS52043B/sr unknown
- 2005-08-11 CA CA2575821A patent/CA2575821C/en not_active Expired - Lifetime
- 2005-08-11 SI SI200531439T patent/SI1778238T1/sl unknown
- 2005-08-11 CN CNA2005800352739A patent/CN101039676A/zh active Pending
- 2005-08-11 MX MX2007001855A patent/MX2007001855A/es active IP Right Grant
- 2005-08-11 PL PL05778137T patent/PL1778238T3/pl unknown
- 2005-08-11 CN CN201610003590.2A patent/CN105640874A/zh active Pending
- 2005-08-11 EA EA200700389A patent/EA014237B1/ru not_active IP Right Cessation
- 2005-08-11 KR KR1020077005957A patent/KR101235092B1/ko not_active Expired - Fee Related
- 2005-08-11 ME MEP-2011-184A patent/ME01264B/me unknown
- 2005-08-11 NZ NZ553815A patent/NZ553815A/en not_active IP Right Cessation
- 2005-08-11 JP JP2007526359A patent/JP5048491B2/ja not_active Expired - Lifetime
- 2005-08-11 HR HR20110966T patent/HRP20110966T1/hr unknown
- 2005-08-12 TW TW094127587A patent/TWI371278B/zh not_active IP Right Cessation
- 2005-08-12 PE PE2009001171A patent/PE20100447A1/es not_active Application Discontinuation
- 2005-08-12 PE PE2009000399A patent/PE20091583A1/es not_active Application Discontinuation
- 2005-08-12 PE PE2005000937A patent/PE20060645A1/es not_active Application Discontinuation
- 2005-08-12 AR ARP050103382A patent/AR050918A1/es unknown
- 2005-08-12 UY UY29060A patent/UY29060A1/es not_active Application Discontinuation
- 2005-08-12 MY MYPI20053807A patent/MY147799A/en unknown
-
2007
- 2007-01-15 ZA ZA200700425A patent/ZA200700425B/xx unknown
- 2007-02-13 IL IL181306A patent/IL181306A/en not_active IP Right Cessation
- 2007-02-14 EC EC2007007250A patent/ECSP077250A/es unknown
- 2007-02-21 NO NO20070984A patent/NO20070984L/no not_active Application Discontinuation
-
2009
- 2009-02-06 US US12/366,730 patent/US8445675B2/en active Active
-
2012
- 2012-01-05 CY CY20121100009T patent/CY1112211T1/el unknown
-
2013
- 2013-04-23 US US13/868,591 patent/US20130245013A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20100447A1 (es) | Solucion acuosa inyectable que contiene 4-[[(7r)-8-isopropil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-tetrahidropteridin-2-il]amino]-3-metoxi-n-[(1-ciclopropil-4-piperazinil)fenil]benzamida | |
| PE20060424A1 (es) | Polimorfos de 4-[[(7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil]amino]-3-metoxi-n-(1-metil-4-piperidinil) benzamida como inhibidores de quinasa | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| CY1111747T1 (el) | 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα | |
| PE20030976A1 (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| GT200100141A (es) | Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamicos. | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| PE20081579A1 (es) | Derivados de benzamida como agonistas del receptor | |
| AR078151A1 (es) | Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas. | |
| EE04911B1 (et) | Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks | |
| MX2011012627A (es) | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. | |
| CY1114200T1 (el) | Ναφθυλοοξικα οξεα | |
| ATE536172T1 (de) | Ezetimibzusammensetzungen | |
| SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| PE20121528A1 (es) | Metodos para administrar agentes hipoglucemiantes de larga duracion | |
| NZ593524A (en) | A nonapeptide with anti-tumour activity | |
| TW200605909A (en) | Pharmaceutical preparation of recombinant factor VIII lyophilized without albumin as a stabilizer | |
| PE20080887A1 (es) | Composiciones de carbamatos de fenilalquilo | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| WO2010106557A3 (en) | Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof | |
| TW200626527A (en) | Novel hexafluoroisopropanol derivatives | |
| PE20060533A1 (es) | Derivados de dicetopiperazina como antagonistas del receptor de oxitocina | |
| ATE295845T1 (de) | Prucaloprid-n-oxid | |
| AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |